Drugs / T-817MA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02693197 | Feb → Aug 2016 | — | FUJIFILM Toyama Chemical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04191486 | Dec 2019 → Feb 2023 | cognitive impairment with or without cerebellar ataxia | FUJIFILM Toyama Chemical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00663936 | Apr 2008 → May 2011 | Alzheimer disease | FUJIFILM Toyama Chemical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-817MA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00663936 ↗ |
| Known as | T-817 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02693197 ↗ |
| Route | Oral | “A single oral dose” NCT02693197 ↗ |